Results 1 to 10 of about 87,818 (186)

New Avenues for Phosphodiesterase Inhibitors in Asthma [PDF]

Journal of Experimental Pharmacology, 2021
Maria Gabriella Matera,1 Josuel Ora,2 Francesco Cavalli,2 Paola Rogliani,2,3 Mario Cazzola3 1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Respiratory Diseases Unit, “Tor Vergata&rdquo ...
Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M   +4 more
doaj   +2 more sources

Effect of phosphodiesterase inhibitors on platelet function [PDF]

Biochemistry and Biophysics Reports
Phosphodiesterase enzymes (PDEs) play a pivotal role in regulating platelet activity by modulating intracellular levels of cAMP and cGMP. Modulation of PDE-2, -3 and -5 activity by suitable inhibitors has been found to reduce platelet activity, and thus ...
Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz   +7 more
doaj   +2 more sources

Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy [PDF]

JACC: Basic to Translational Science, 2016
Molecular mechanisms of Trypanosoma cruzi (Tc)-induced Chagasic cardiomyopathy (CCM) are not well understood. The NO-cGMP-PKG1α pathway maintains cardiac homeostasis and inotropy and may be disturbed due to phosphodiesterase (PDE5)-mediated cGMP ...
Jian-jun Wen, PhD, Xianxiu Wan, MS, John Thacker, BS, Nisha Jain Garg, PhD   +3 more
doaj   +2 more sources

The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review

Frontiers in Pharmacology, 2022
Phosphodiesterase-1 (PDE1) is a versatile enzyme that has surprisingly received considerable attention as a possible therapeutic target in Alzheimer’s disease (AD) because it maintains the homeostasis of 3ʹ,5ʹ-cyclic adenosine monophosphate (cAMP) and 3ʹ,
Nazir Ahmad, Kaisun Nesa Lesa, Ari Sudarmanto, Nanang Fakhrudin, Nanang Fakhrudin, Zullies Ikawati   +5 more
doaj   +1 more source

Phosphodiesterase Inhibitors: Present and Future

Barcelona Respiratory Network Reviews, 2023
Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj   +1 more source

Multi-target Natural and Nature-Inspired Compounds against Neurodegeneration: A Focus on Dual Cholinesterase and Phosphodiesterase Inhibitors

Applied Sciences, 2021
Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease.
Giovanni Ribaudo, Maurizio Memo, Alessandra Gianoncelli   +2 more
doaj   +1 more source

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis [PDF]

EBioMedicine, 2016
Bintou Ahmadou Ahidjo, William R. Bishai
doaj   +2 more sources

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. [PDF]

, 2013
The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
A Hatzelmann, Andreas Eigler, B Bielekova, B Siegmund, B Sinha, Britta Siegmund, CO Elson, Daniela S. Bundschuh, DC Grootendorst, DK Podolsky, DS Bundschuh, E Dony, F Loher, Florian Rieder, G Hartmann, G Kojouharoff, H Ichikawa, Hans-Anton Lehr, HS Cooper, HW Ziegler-Heitbrock, I Sturgess, J Keane, J Semmler, KF Rabe, KH Banner, KH Banner, LM Fabbri, M Tomoyose, N Diaz-Granados, N Sommer, P Rutgeerts, P Rutgeerts, PM Calverley, RK Kumar, S Schreiber, S Videla, SF Ziegler, SH Murch, SN Murthy, Stefan Bereswill, Stefan Endres, TJ Torphy, U Nyman, WJ Sandborn   +43 more
core   +8 more sources

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors

Pulmonary Circulation, 2020
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz, Jerrold W. Hill, Cassandra A. Lickert, Rolin L. Wade, Michele R. Cole, Yuen Tsang, William Drake   +6 more
doaj   +1 more source

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis

Frontiers in Pharmacology, 2020
Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients’ quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance.
Viera Janosova, Vladimir Calkovsky, Heiko Pedan, Estera Behanova, Andrej Hajtman, Andrea Calkovska   +5 more
doaj   +1 more source